Original Research J Clin Psychiatry May 2026

Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Article Summary Adults with ADHD commonly present with depression and anxiety symptoms, yet these patients are routinely excluded from ADHD trials, leaving clinicians to treat a high-burden population with limited evidence. This study addresses whether viloxazine ER can improve ADHD symptoms in adults who also have prominent mood and/or anxiety symptoms while being used alone or alongside other psychiatric medications. FAQ Did viloxazine ER improve ADHD symptoms in adults who also had depression or anxiety symptoms? 10 questions
Key Takeaways In this symptomatic comorbid population, ADHD improvement was substantial by week 14/EOS, with mean (SD) AISRS and ASRSv1.1-SC total score changes of −17.3 (11.34) and −28.4 (14.89), and 71.8% and 45.6% of participants achieved ≥30% and ≥50% AISRS reduction, respectively. 6 takeaways Clinical Guide How should clinicians monitor safety after starting viloxazine ER in adults with ADHD and comorbid depression and/or anxiety symptoms? 7 steps Clinical Guide How should clinicians initiate viloxazine ER in adults with ADHD who also have prominent depression and/or anxiety symptoms? 6 steps